Introduction of higher doses of deferasirox: Better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 633-641

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

chelation therapy; deferasirox; deferiprone; deferoxamine; Iron overload; thalassemia; toxicity

Indexed keywords

ANTACID AGENT; ANTICOAGULANT AGENT; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; MIDAZOLAM; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; POLYPHENOL; REPAGLINIDE; RIFAMPICIN; RITONAVIR; SIMVASTATIN; TETRACYCLINE; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

AGRANULOCYTOSIS; ALOPECIA; ANAPHYLAXIS; APLASTIC ANEMIA; AREA UNDER THE CURVE; CARDIOTOXICITY; CHEMICAL CARCINOGENESIS; COPPER BLOOD LEVEL; DEGENERATIVE DISEASE; DEVELOPING COUNTRY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DUODENUM ULCER; ERYTHEMA MULTIFORME; ESOPHAGITIS; EYE TOXICITY; FANCONI RENOTUBULAR SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACIDOSIS; MUCORMYCOSIS; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PANCYTOPENIA; PATIENT MONITORING; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STOMACH DISEASE; STOMACH ULCER; THALASSEMIA; THROMBOCYTOPENIA; YERSINIOSIS; ZINC BLOOD LEVEL; CHELATION THERAPY; DRUG COMBINATION; DRUG INTERACTION; HEART MUSCLE; METABOLISM;

BENZOATES; CHELATION THERAPY; DEFEROXAMINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYOCARDIUM; PYRIDONES; TRIAZOLES;

EID: 77953768780     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.497138     Document Type: Review

References (35)

1. Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis pharmaceutical corporation USA (NDA 21-882), 1-12 October 2006
2. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-1602
3. Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005;366:804
4. Kolnagou A, Economides CH, Eracleous E, Kontoghiorghes GJ. Long term comparative studies inthalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008;32:41-47
5. Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin 2009;33:332-338
6. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007;6:236-239
7. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: advances with deferiprone/ deferoxamine combination and concerns on deferasirox's safety, efficacy and costs. Hemoglobin 2008;32:1-15
8. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassaemia. Blood 2010;115:2364-2371
9. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin 2006;30:239-249
10. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355
11. Tanner MA, Galanello R, Dessi C, et al. A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884
12. Kontoghiorghes GJ. Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert Opin Drug Saf 2008;7:1-2
13. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-566
14. Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis 2009;54:931-934
15. Papadopoulos N, Vasiliki A, Aloizos G, et al. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 2010;44:219-221
16. Exjade (deferasirox) Prescribing Information Novartis. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm200850.htm. [1-15 January 2010]
17. Hohneker JA. Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis pharmaceutical corporation USA, 1-6 February 2010
18. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26(8):553-584 (Pubitemid 36724096)
19. Sofroniadou K, Drossou M, Foundoulaki L, et al. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf 1990;5:152-154
20. Robins-Browne RM, Pipic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983;2:1372
21. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991;18:660-667
22. Polson RJ, Jawad AS, Bomford A, et al. Treatment of rheumatoid arthritis with desferrioxamine. Q J Med 1986;61:1153-1158
23. Kontoghiorghes GJ, Kolnagou A, Peng CT, et al. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf 2010;9:201-206
24. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000;23:211-223
25. Beau-Salinas F, Guitteny MA, Donadieu J, et al. High doses of deferiprone may be associated with cerebellar syndrome. BMJ 2009;338:a2319
26. Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin 2008;32:608-615
27. Morales NP, Yamanont P, Jirasomprasert T, et al. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int J Clin Pharmacol Ther 2009;47:358-364
28. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-29
29. Tefler P, Goen PG, Christou S, et al. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-1192
30. Kolnagou A, Kontoghiorghes GJ. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol 2010. [Epub ahead of print]
31. Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-475
32. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:741-752
33. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010. [Epub ahead of print]
34. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587
35. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009;145:245-254